PPAR ligands and cardiovascular disorders: Friend or foe

Current Molecular Pharmacology

Volumn 5, Issue 2, 2012, Pages 219-223

  Balakumar, Pitchai ^a   Jagadeesh, Gowraganahalli ^b  

^a Rajendra Institute of Technology and Sciences   (India)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOPRENALINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SIMVASTATIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; BLADDER TUMOR; BLOOD VESSEL TONE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; FATTY ACID METABOLISM; FLUID RETENTION; GLUCOSE METABOLISM; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LIPID METABOLISM; MONOTHERAPY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PERIPHERAL EDEMA; PLEIOTROPY; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; WEIGHT GAIN;

EID: 84861740440     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874-470211205020219     Document Type: Editorial

References (47)

1. Sugden, M.C.; Zariwala, M.G.; Holness, M.J. PPARs and the orchestration of metabolic fuel selection. Pharmacol. Res., 2009, 60, 141-150.
2. Holness, M.J.; Samsuddin, S.; Sugden, M.C. The role of PPARs in modulating cardiac metabolism in diabetes. Pharmacol. Res., 2009, 60, 185-194.
3. Balakumar, P.; Rose, M.; Singh, M. PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology, 2007, 80, 1-10.
4. European Medicines Agency: European medicines agency recommends suspension of Avandia, Avandamet and Avaglim. Anti-diabetes medication to be taken off the market. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf (2010). EMA/585784/2010 [accessed on July 21, 2011]
5. Dreyer, C.; Krey, G.; Keller, H.; Givel, F.; Helftenbein, G.; Wahli, W. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell, 1992, 68, 879-887.
6. Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 1990, 347, 645-650.
7. Nuclear Receptors Nomenclature Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell, 1999, 97, 161-163.
8. Berger, J.P.; Akiyama, T.E.; Meinke, P.T. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci., 2005, 26, 244-251.
9. Goldberg, R.B.; Kendall, D.M.; Deeg, M.A.; Buse, J.B.; Zagar, A.J.; Pinaire, J.A.; Tan, M.H.; Khan, M.A.; Perez, A.T.; Jacober, S.J.; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care, 2005, 28, 1547-1554.
10. Balakumar, P.; Rose, M.; Ganti, S.S.; Krishan, P.; Singh, M. PPAR dual agonists: are they opening Pandora's Box? Pharmacol. Res., 2007, 56, 91-98.
11. Zambon, A.; Cusi, K. The role of fenofibrate in clinical practice. Diab. Vasc. Dis. Res., 2007, 4, S15-20.
12. Jackevicius, C.A.; Tu, J.V.; Ross, J.S.; Ko, D.T.; Carreon, D.; Krumholz, H.M. Use of fibrates in the United States and Canada. JAMA, 2011, 305, 1217-1224.
13. Balakumar, P.; Rohilla, A.; Mahadevan, N. Pleiotropic actions of fenofibrate on the heart. Pharmacol. Res., 2011, 63, 8-12.
14. Balakumar, P.; Jagadeesh, G. Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared? Pharmacol. Res., 2010, 62, 365-383.
15. Arora, M.K.; Reddy, K.; Balakumar, P. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. Eur. J. Pharmacol., 2010, 636, 137-144.
16. Balakumar, P.; Arora, M.K.; Singh, M. Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacol. Res., 2009, 60, 170-173.
17. Ogata, T.; Miyauchi, T.; Sakai, S.; Takanashi, M.; Irukayama-Tomobe, Y.; Yamaguchi, I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J. Am. Coll. Cardiol., 2004, 43, 1481-1488.
18. Ogata, T.; Miyauchi, T.; Sakai, S.; Irukayama-Tomobe, Y.; Goto, K.; Yamaguchi, I. Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure overloaded rat hearts. Clin. Sci., 2002, 103, 284S-288S.
19. Diep, Q.N.; Benkirane, K.; Amiri, F.; Cohn, J.S.; Endemann, D.; Schiffrin, E.L. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J. Mol. Cell. Cardiol., 2004, 36, 295-304.
20. Yuan, J.; Wu, J.; Han, Z.G. Fenofibrate improves energy metabolism and attenuates isoproterenol induced acute myocardial ischemic injury in rats via PPAR alpha activation. Zhonghua Xin Xue Guan Bing Za Zhi, 2008, 36, 847-850.
21. Balakumar, P.; Chakkarwar, V.A.; Singh, M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol. Cell. Biochem., 2009, 320, 149-162.
22. Kaur, J.; Reddy, K.; Balakumar, P. The novel role of fenofibrate in preventing nicotine and sodium arsenite-induced vascular endothelial dysfunction in the rat. Cardiovasc. Toxicol., 2010, 10, 227-238.
23. Scott, R.; O'Brien, R.; Fulcher, G.; Pardy, C.; D'Emden, M.; Tse, D.; Taskinen, M.R.; Ehnholm, C.; Keech, A.; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care, 2009, 32, 493-498.
24. Ginsberg, H.N.; Elam, M.B.; Lovato, L.C.; Crouse, J.R. 3rd; Leiter, L.A.; Linz, P.; Friedewald, W. T; Buse, J.B.; Gerstein, H.C.; Probstfield, J.; Grimm, R.H.; Ismail-Beigi, F.; Bigger, J.T.; Goff, D.C. Jr.; Cushman, W.C.; Simons-Morton, D. G.; Byington, R.P.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. New Engl. J. Med.; 2010, 362:1563-1574.
25. Fazio, S. More clinical lessons from the FIELD study. Cardiovasc. Drugs Ther., 2009, 23, 235-241.
26. Nissen, S.E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl. J. Med., 2007, 356, 2457-2471.
27. Hernandez, A.V.; Usmani, A.; Rajamanickam, A.; Moheet, A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus. Am. J. Cardiovasc. Drugs, 2011, 11, 115-128.
28. Lincoff, A.M.; Wolski, K.; Nicholls, S.J.; Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA, 2007, 298, 1180-1188.
29. Singh, S.; Loke, T.K.; Furberg, C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA, 2007, 298, 1189-1195.
30. Lago, R.M.; Singh, P.P.; Nesto, R.W. Congestive heart failure and cardiovascular death in patients with pre-diabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet, 2007, 370, 1129-1136.
31. Rosen, C.J. The rosiglitazone story--lessons from an FDA Advisory Committee meeting. New Engl. J. Med., 2007, 357, 844-846.
32. Rosen, C.J. Revisiting the rosiglitazone story--lessons learned. New Engl. J. Med., 2010, 363, 803-806.
33. Schernthaner, G.; Chilton R.J. Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us? Diabetes Obes. Metab., 2010, 12, 1023-1035.
34. Kaul, S.; Bolger, A.F.; Herrington, D.; Giugliano, R.P.; Eckel, R.H. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation, 2010, 121, 1868-1877.
35. http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm. [accessed on June 28, 2011]
36. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/06/news_detail_001284.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1. [accessed on July 21, 2011]
37. http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---June/13/Germany-joins-France-in-suspending-use-of-pioglitazone-while-EMA-safety-reviewis-ongoing [accessed on July 21, 2011].
38. Sugden, M.C.; Warlow, M.P.; Holness, M.J. The involvement of PPARs in the causes, consequences and mechanisms for correction of cardiac lipotoxicity and oxidative stress. Curr. Mol. Pharmacol., 2012, 5(2), 224-240.
39. Huang, T. H-W.; Roufogalis, B.D. Healing the diabetic heart: Modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs). Curr. Mol. Pharmacol., 2012, 5(2), 241-247.
40. Sugawara, A.; Uruno, A.; Matsuda, K.; Funato, T.; Saito-Hakoda, A.; Kudo, M.; Ito, S. Effects of PPAR[agonists against vascular and renal dysfunction. Curr. Mol. Pharmacol., 2012, 5(2), 248-254.
41. Sarma, S. Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits? Curr. Mol. Pharmacol., 2012, 5(2), 255-263.
42. Rubenstrunk, A.; Hanf, R.; Hum, D.W.; Fruchart, J-C.; Staels, B. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta, 2007, 1771, 1065-1081.
43. Wang, X. Assessment of cardiac safety for PPAR[agonists in rodent models of heart failure: A translational medicine perspective. Curr. Mol. Pharmacol., 2012, 5(2), 264-271.
44. Derosa, G.; Maffioli, P. Peroxisome proliferator-activated receptor[(PPAR() agonists on glycemic control, lipid profile and cardiovascular risk. Curr. Mol. Pharmacol., 2012, 5(2), 272-281.
45. Salomone, S.; Drago, F. Effects of PPARγ ligands on vascular tone. Curr. Mol. Pharmacol., 2012, 5(2), 282-291.
46. Nagao, S.; Yamaguchi, T. PPARγ agonists in polycystic kidney disease with frequent development of cardiovascular disorders. Curr. Mol. Pharmacol. 2012, 5(2), 292-300.
47. Balakumar, P.; Mahadevan, N. Interplay between statins and PPARs in improving cardiovascular outcomes: A double-edged sword? Br. J. Pharmacol., 2012, 165, 373-379.